The ultimate goal of precision medicine is a unique drug for each patient. However, this N-of-1 model directly conflicts with the current economic and regulatory system, which incentivizes developing drugs for large populations to recoup massive R&D and approval costs.

Advanced AI models are ineffective in clinical settings without a robust data layer. Ambience had to solve fundamental problems like pulling messy context from inconsistent EHRs and preserving 'decision traces,' which are often destroyed by existing systems with mutable data structures.

We possess millions of data points on interventions, but they are useless to AI models because they're trapped in thousands of disparate EMRs in varied formats. The challenge is not generating more data, but solving the human incentive and alignment problems required to create unified data registries.

Even with advanced imaging for diseases like Alzheimer's, adoption stalls if diagnostic results don't change patient management. Physicians won't use a test that answers an academic question but doesn't lead to an effective treatment, rendering the technology clinically irrelevant without answering the 'so what?' question.

The traditional drug-centric trial model is failing. The next evolution is trials designed to validate the *decision-making process* itself, using platforms to assign the best therapy to heterogeneous patient groups, rather than testing one drug on a narrow population.

The primary challenge holding back precision medicine is not a lack of data or innovation. Instead, it's the operational difficulty of integrating and interpreting complex, siloed information quickly enough to make it clinically actionable for individual patients. The focus must shift from accumulation to execution.

Despite billions invested over 20 years in targeted and genome-based therapies, the real-world benefit to cancer patients has been minimal, helping only a small fraction of the population. This highlights a profound gap and the urgent need for new paradigms like functional precision oncology.

The progress of AI in predicting cancer treatment is stalled not by algorithms, but by the data used to train them. Relying solely on static genetic data is insufficient. The critical missing piece is functional, contextual data showing how patient cells actually respond to drugs.

Advanced health tech faces a fundamental problem: a lack of baseline data for what constitutes "optimal" health versus merely "not diseased." We can identify deficiencies but lack robust, ethnically diverse databases defining what "great" health looks like, creating a "North Star" problem for personalization algorithms.